Kumar Neil — SEC Form 4 Insider Trading Activity

Summary

Updated Jul 16, 2026

Kumar Neil has filed 5 SEC Form 4 filings across 2 companies in the last 90 days — selling. Lifetime open-market sales: $51.61M.

Profile

Kumar Neil

Neil Kumar is the Chief Executive Officer and a Director at BridgeBio Pharma, Inc., a biotechnology company focused on developing treatments for genetic diseases. He has played a significant role in advancing the company's late-stage pipeline, which includes innovative therapies for various Mendelian disorders and oncology.

RoleInsider
Notability50/100

Board memberships

Awards & honors

Recent Transactions

DateTickerCompanyCodeSharesPriceValue
2026-06-08BBIOBridgeBio Pharma, Inc.S — Open-market sale4.4K$68.96$304K
2026-06-08BBIOBridgeBio Pharma, Inc.S — Open-market sale8.4K$67.88$573K
2026-06-08BBIOBridgeBio Pharma, Inc.S — Open-market sale7.1K$67.20$480K
2026-06-08BBIOBridgeBio Pharma, Inc.S — Open-market sale4.4K$68.96$305K
2026-06-08BBIOBridgeBio Pharma, Inc.S — Open-market sale8.4K$67.88$573K
2026-06-08BBIOBridgeBio Pharma, Inc.S — Open-market sale7.1K$67.20$480K
2026-06-08BBIOBridgeBio Pharma, Inc.S — Open-market sale450$68.27$31K
2026-06-08BBIOBridgeBio Pharma, Inc.S — Open-market sale15.9K$67.74$1.08M
2026-06-08BBIOBridgeBio Pharma, Inc.S — Open-market sale1.4K$66.72$95K
2026-06-08BBIOBridgeBio Pharma, Inc.S — Open-market sale2.2K$65.72$145K
2026-06-08BBIOBridgeBio Pharma, Inc.S — Open-market sale450$68.27$31K
2026-06-08BBIOBridgeBio Pharma, Inc.S — Open-market sale15.9K$67.74$1.08M
2026-06-08BBIOBridgeBio Pharma, Inc.S — Open-market sale1.4K$66.72$95K
2026-06-08BBIOBridgeBio Pharma, Inc.S — Open-market sale2.2K$65.72$145K
2026-05-26BBIOBridgeBio Pharma, Inc.S — Open-market sale800$70.92$57K
2026-05-26BBIOBridgeBio Pharma, Inc.S — Open-market sale11.2K$70.48$793K
2026-05-26BBIOBridgeBio Pharma, Inc.S — Open-market sale5.1K$69.22$351K
2026-05-26BBIOBridgeBio Pharma, Inc.S — Open-market sale6.7K$68.30$459K
2026-05-26BBIOBridgeBio Pharma, Inc.S — Open-market sale2.3K$67.57$152K
2026-05-19BBIOBridgeBio Pharma, Inc.F — Tax withholding / forfeiture36.2K$66.13$2.40M

Companies — Last 90 Days

Frequently Asked Questions

Who is Kumar Neil?

Neil Kumar is the Chief Executive Officer and a Director at BridgeBio Pharma, Inc., a biotechnology company focused on developing treatments for genetic diseases. He has played a significant role in advancing the company's late-stage pipeline, which includes innovative therapies for various Mendelian disorders and oncology.…

How many SEC Form 4 filings has Kumar Neil submitted recently?

5 primary Form 4 filings in the last 90 days, covering 2 companies.

Has Kumar Neil been buying or selling stock?

Recorded transactions: 0 open-market purchases () and 100 open-market sales ($51.61M) across all tracked filings.

Where can I see all of Kumar Neil's SEC filings?

All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.

Learn More

Open the live Kumar Neil profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.